Annual Report

Overview

The report describes a year of clinical and corporate progress for the company. Veyonda's DARRT-1 study achieved full enrolment in late-stage prostate cancer, while the LuPIN-1 study expanded to 56 patients. The report also highlights Nyrada's progress in building its drug-development foundation ahead of a planned Australian stock exchange listing.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2019
Period: Ends 30 June 2019
Publication date: 26 September 2019
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services